Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India

Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India

PURPOSEPrevention of chemotherapy-induced nausea and vomiting with currently recommended NK1 receptor antagonist–based triplet during carboplatin (AUC ≥4) chemotherapy appears inadequate. A comparative study between olanzapine and NK1 receptor antagonist–based combination is lacking.METHODSThis was...

Full description

Saved in:
Bibliographic Details
Main Authors: Sneh Bhargave, Vinod Sharma, Babita Kataria, Atul Batra, Deepam Pushpam, Aparna Sharma, Raja Pramanik, Prabhat S. Malik, Ranjit. K. Sahoo, Sachin Khurana, Vishwajeet Singh, Sameer Bakhshi, Atul Sharma, Lalit Kumar, Akash Kumar
Format: Article
Language:English
Published: American Society of Clinical Oncology 2025-04-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO.24.00166
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://ascopubs.org/doi/10.1200/GO.24.00166

Similar Items